Trial · NCT01097629
Adverse events304
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 304
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | headache | Nervous system disorders | Suvorexant LD (TRT Phase) | 19 | 239 | 22 |
| other | headache | Nervous system disorders | Suvorexant HD (TRT Phase) | 29 | 387 | 32 |
| other | headache | Nervous system disorders | Placebo (TRT Phase) | 22 | 383 | 22 |
| other | headache | Nervous system disorders | Suvorexant LD (RO, After Suvorexant LD in TRT) | 0 | 97 | 0 |
| other | headache | Nervous system disorders | Placebo (RO, After Suvorexant LD in TRT) | 1 | 108 | 1 |
| other | headache | Nervous system disorders | Suvorexant HD (RO, After Suvorexant HD in TRT) | 3 | 173 | 3 |
| other | headache | Nervous system disorders | Placebo (RO, After Suvorexant HD in TRT) | 1 | 171 | 1 |
| other | headache | Nervous system disorders | Placebo (RO, After Placebo in TRT) | 4 | 327 | 4 |
| other | headache | Nervous system disorders | Suvorexant LD (TRT Phase): Follow-up | 0 | 239 | 0 |
| other | headache | Nervous system disorders | Suvorexant HD (TRT Phase): Follow-up | 2 | 387 | 2 |
| other | headache | Nervous system disorders | Placebo (TRT Phase): Follow-up | 0 | 383 | 0 |
| other | headache | Nervous system disorders | Suvorexant LD (RO, After Suvorexant LD in TRT): Follow-up | 0 | 97 | 0 |
| other | headache | Nervous system disorders | Placebo (RO, After Suvorexant LD in TRT): Follow-up | 1 | 108 | 1 |
| other | headache | Nervous system disorders | Suvorexant HD (RO, After Suvorexant HD in TRT): Follow-up | 0 | 173 | 0 |
| other | headache | Nervous system disorders | Placebo (RO, After Suvorexant HD in TRT): Follow-up | 0 | 171 | 0 |
| other | headache | Nervous system disorders | Placebo (RO, After Placebo in TRT): Follow-up | 1 | 327 | 1 |
| other | somnolence | Nervous system disorders | Suvorexant LD (TRT Phase) | 20 | 239 | 21 |
| other | somnolence | Nervous system disorders | Suvorexant HD (TRT Phase) | 40 | 387 | 44 |
| other | somnolence | Nervous system disorders | Placebo (TRT Phase) | 12 | 383 | 13 |
| other | somnolence | Nervous system disorders | Suvorexant LD (RO, After Suvorexant LD in TRT) | 0 | 97 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01097629/events